https://orcid.org/0000-0003-1194-0068
References
- Jonas JB, Aung T, Bourne RR, et al. Glaucoma. Lancet 2017;390:2183–93.
- Mincione F, Nocentini A, Supuran CT. Advances in the discovery of novel agents for the treatment of glaucoma. Expert Opin Drug Discov 2021;16:1209–25.
- Guglielmi P, Carradori S, Campestre C, Poce G. Novel therapies for glaucoma: a patent review (2013–2019). Expert Opin Ther Pat 2019;29:769–80.
- Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther 2015;31:63–77.
- Kanner E, Tsai JC. Glaucoma medications. Drugs Aging 2006;23:321–32.
- a) Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:595–781. b) Supuran CT, Casini A, Scozzafava A, Development of sulfonamide carbonic anhydrase inhibitors. In: Supuran CT, Scozzafava A, Conway J, eds. Carbonic anhydrase – Its inhibitors and activators. Boca Raton (FL): CRC Press; 2004:67–147. c) Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J Med Chem 2000;43:4542–51.
- Maurice DM, Mishima S. Ocular pharmacology. In: Sears M, ed. Handbook of experimental pharmacology. Berlin-Heidelberg: Springer-Verlag; 1984:16–19.
- Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985;26:584–7.
- Hämäläinen KM, Kananen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997;38:627–34.
- Krasavin M, Korsakov M, Dorogov M, et al. Probing the 'bipolar' nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms. Eur J Med Chem 2015;101:334–47.
- Ferraroni M, Lucarini L, Masini E, et al. 1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: potency is supported by X-ray crystallography of two leads. Bioorg Med Chem 2017;25:4560–5.
- Broadway DS, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging 2015;32:569–81.
- Yadav KS, Rajpurohit R, Sharma S. Glaucoma: current treatment and impact of advanced drug delivery systems. Life Sci 2019;221:362–91.
- Del Amo EM, Rimpelä A-K, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. *Prog Retin Eye Res 2017;57:134–85.
- Kalinin S, Valtari A, Ruponen M, et al. Highly hydrophilic 1,3-oxazol-5-yl benzenesulfonamide inhibitors of carbonic anhydrase II for reduction of glaucoma-related intraocular pressure. Bioorg Med Chem 2019;27:115086.
- Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem 2021;36:561–80.
- Scozzafava A, Supuran CT. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem 2014;75:349–59.
- Lomelino CL, Andring JT, McKenna R. Crystallography and its impact on carbonic anhydrase research. Int J Med Chem 2018;2018:9419521.
- Pilipenko I, Korzhikov-Vlakh V, Valtari A, et al. Mucoadhesive properties of nanogels based on stimuli-sensitive glycosaminoglycan-graft-pNIPAAm copolymers. Int J Biol Macromol 2021;186:864–72.
- Kidron H, Vellonen K-S, Amo E, et al. Prediction of the corneal permeability of drug-like compounds. Pharm Res 2010;27:1398–407.
- Ramsay E, Del Amo E, Toropainen E, et al. Corneal and conjunctival drug permeability: systematic comparison and pharmacokinetic impact in the eye. Eur J Pharm Sci 2018;119:83–9.
- Ramsay E, Ruponen M, Picardat T, et al. Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of in silico model. J Pharm Sci 2017;106:2463–71.